Mitochondria-targeting symmetric diiminoguanidines: potent and selective anticancer agents against pancreatic tumors
Open Access
- 29 December 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (2) , 1099-1106
Abstract
Pancreatic cancer remains one of the deadliest malignancies of the 21st century, with a five-year survival rate below 12%.Keywords
Funding Information
- Université de Montréal
- Canada Foundation for Innovation
- Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03128)
This publication has 37 references indexed in Scilit:
- The Role of Mitochondria in ApoptosisAnnual Review of Genetics, 2009
- Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreasCore Evidence, 2007
- Mitochondrial Medicine: Pharmacological targeting of mitochondria in diseaseBritish Journal of Pharmacology, 2007
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003
- Gemcitabine Therapy in Patients with Advanced Pancreatic CancerThe Korean Journal of Internal Medicine, 2002
- An Introduction to Pancreatic Adenocarcinoma Genetics, Pathology and TherapyCancer Biology & Therapy, 2002
- Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic CancerJournal of Clinical Oncology, 2002
- Effects of 5-Fluorouracil and Leucovorin in the Treatment of Pancreatic–Biliary Tract AdenocarcinomasAmerican Journal of Clinical Oncology, 2000
- Mitochondria and ApoptosisScience, 1998
- Gemcitabine: metabolism, mechanisms of action, and self-potentiation.1995